For the quarter ending 2025-09-30, CLDX had $12,993K increase in cash & cash equivalents over the period. -$49,068K in free cash flow.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -67,044 | -110,396 |
| Depreciation and amortization | 824 | 1,740 |
| Amortization and premium of marketable securities, net | 1,018 | 3,955 |
| Loss on sale or disposal of assets | -6 | -6 |
| Stock-based compensation expense | 8,801 | 18,507 |
| Accounts and other receivables | 0 | -610 |
| Prepaid and other current assets | 2,785 | -3,020 |
| Other assets | 64 | -447 |
| Accounts payable and accrued expenses | 13,062 | -6,632 |
| Other liabilities | -410 | -1,724 |
| Net cash used in operating activities | -48,628 | -98,377 |
| Sales and maturities of marketable securities | 116,915 | 367,873 |
| Purchases of marketable securities | 55,628 | 274,080 |
| Acquisition of property and equipment | 440 | 993 |
| Net cash provided by (used in) investing activities | 60,847 | 92,800 |
| Proceeds from issuance of stock from employee benefit plans | 774 | 265 |
| Net cash provided by financing activities | 774 | 265 |
| Net increase in cash and cash equivalents | 12,993 | -5,312 |
| Cash and cash equivalents at beginning of period | 28,356 | - |
| Cash and cash equivalents at end of period | 36,037 | - |
Celldex Therapeutics, Inc. (CLDX)
Celldex Therapeutics, Inc. (CLDX)